AbbVie Debt to Equity Ratio 2010-2018 | ABBV

Current and historical debt to equity ratio values for AbbVie (ABBV) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. AbbVie debt/equity for the three months ending September 30, 2018 was 8.70.
AbbVie Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $36.49B $-2.92B -12.49
2018-06-30 $30.58B $-3.38B -9.06
2018-03-31 $30.91B $3.55B 8.70
2017-12-31 $30.95B $5.10B 6.07
2017-09-30 $33.97B $6.69B 5.08
2017-06-30 $33.82B $6.01B 5.63
2017-03-31 $36.53B $5.00B 7.31
2016-12-31 $36.44B $4.64B 7.86
2016-09-30 $37.28B $6.47B 5.76
2016-06-30 $37.33B $5.64B 6.62
2016-03-31 $29.49B $4.64B 6.35
2015-12-31 $29.24B $3.95B 7.41
2015-09-30 $31.36B $4.86B 6.45
2015-06-30 $27.12B $5.50B 4.93
2015-03-31 $10.68B $1.38B 7.76
2014-12-31 $10.54B $1.74B 6.05
2014-09-30 $14.47B $4.65B 3.12
2014-06-30 $14.47B $5.22B 2.77
2014-03-31 $14.39B $4.70B 3.06
2013-12-31 $14.29B $4.49B 3.18
2013-09-30 $14.38B $3.58B 4.02
2013-06-30 $14.33B $3.56B 4.03
2013-03-31 $14.60B $2.96B 4.94
2012-12-31 $14.63B $3.36B 4.35
2012-09-30 $0.00B $15.67B 0.00
2012-06-30 $0.00B $11.51B 0.00
2012-03-31 $0.00B $12.05B 0.00
2011-12-31 $0.03B $11.93B 0.00
2011-09-30 $0.00B $0.00B 0.00
2011-06-30 $0.00B $0.00B 0.00
2011-03-31 $0.00B $0.00B 0.00
2010-12-31 $0.00B $15.70B 0.00
2009-12-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $132.702B $28.216B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $388.162B 18.20
Pfizer (PFE) United States $259.069B 14.60
Novartis AG (NVS) Switzerland $204.655B 17.49
Merck (MRK) United States $201.163B 17.43
Eli Lilly (LLY) United States $119.057B 20.93
Sanofi (SNY) France $112.613B 13.94
Novo Nordisk (NVO) Denmark $107.980B 17.54
AstraZeneca (AZN) United Kingdom $105.090B 13.05
GlaxoSmithKline (GSK) United Kingdom $102.669B 13.80
Bristol-Myers Squibb (BMY) United States $85.837B 14.14